Cynthia E. Schairer, PhD, Caryn Kseniya Rubanovich, MS, and Cinnamon S. Bloss, PhD
Questions about data privacy need to be addressed when research institutions negotiate with companies developing mobile health applications. Commercial terms of use and data sharing notifications should be reviewed before use in human subject research settings.
AMA J Ethics. 2018;20(9):E864-872. doi:
10.1001/amajethics.2018.864.
Dr Ariane Lewis discusses how we can navigate uncertainty and ambiguity about brain death by understanding clinical criteria for brain death determination and how our approaches to death are culturally and socially situated.
Dr Esha Bansal joins Ethics Talk to discuss her article, coauthored with Drs Saran Kunaprayoon and Linda P. Zhang: “Opportunities for Global Health Diplomacy in Transnational Robotic Telesurgery.”
Bias toward allopathic medicine in the research funding and publication of study results makes it difficult for physicians and others to find accurate data about the efficacy of non-Western, nonallopathic treatments.
Clinical trials for the blood substitute PolyHeme exposed the possibility for ambiguous interpretation of the FDA’s waiver of informed consent for emergency research.
Erin P. Williams, MBE and Jennifer K. Walter, MD, PhD, MS
Undue influence, which occurs when prospective research participants who otherwise would not enroll are induced to enter studies that might pose significant risks, may also involve social injustices such as unequal payment and participant selection methods that unequally distribute the potential harms and benefits of research.
AMA J Ethics. 2015;17(12):1116-1121. doi:
10.1001/journalofethics.2015.17.12.ecas2-1512.